Search - tctmd.com

Displaying 41 - 60 of 92

Sort: Relevancy | Date

Presentation TCT 2022

The Importance of Addressing Lipids in Patients With Complex PCI

Presenter: Nisha Jhalani

September 19, 2022

Presentation ACC 2022

TRANSLATE-TIMI 70

Presenter: Brian Bergmark

April 04, 2022

Presentation ACC 2022

The PACMAN AMI Randomized Clinical Trial

Presenter: Lorenz Räber

April 04, 2022

Presentation Controversies and Advances 2021

What Diet is Best for Cardiovascular Health?

Presenter: Kim Allan Williams, Sr.

December 03, 2021

Presentation Controversies and Advances 2021

Pathways for Inflammation in Athero-thrombosis Focus on Inflammasome

Presenter: P. K. Shah

December 03, 2021

Presentation Controversies and Advances 2021

EPA Fish Oil: Who Should Receive It?

Presenter: Peter P. Toth

December 03, 2021

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Aloke Finn

September 28, 2019

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Ziad Ali

September 28, 2019

Presentation TCT 2019

What is the Role of the Interventional Cardiologist in Lipid Management?

Presenter: Wolfgang Koenig

September 28, 2019

Presentation TCT 2019

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Presenter: R. Wright

September 28, 2019

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation Controversies and Advances 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

Advertisement

The Importance of Addressing Lipids in Patients With Complex PCI

TRANSLATE-TIMI 70

The PACMAN AMI Randomized Clinical Trial

What Diet is Best for Cardiovascular Health?

Pathways for Inflammation in Athero-thrombosis Focus on Inflammasome

EPA Fish Oil: Who Should Receive It?

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

What is the Role of the Interventional Cardiologist in Lipid Management?

The State of The Art in LDL-C Lowering: Urgent Needs and Unmet Opportunities

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content